Clinical Trial Update: Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy [Phase 4]

View source ↗

Summary

This Phase 4 trial update evaluates the immunogenicity and potential clinical efficacy of the 20-valent pneumococcal conjugate vaccine (PCV20) in lymphoma survi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• PCV20 (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 4 | Status: ACTIVE_NOT_RECRUITING